Dermira Ends Acne Program After Phase III Failure, Tries To Keep Focus On Hyperhidrosis Drug
FDA approval for DRM04 in hyperhidrosis is expected at the end of June, but Phase III data for DRM01 in acne was the main event for investors. CEO Tom Wiggans said Dermira will try to understand what went wrong, while staying focused on DRM04 commercialization and lebrikizumab in Phase IIb.
You may also be interested in...
The Italian-headquartered, Swiss-listed company spun out of Cosmo Pharmaceuticals has moved a step closer to having the first topical anti-androgen drug approved for acne.
US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.
As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.